Laboratório de Química do Estado Sólido
 LQES NEWS  portfólio  em pauta | pontos de vista | vivência lqes | lqes cultural | lqes responde 
 o laboratório | projetos e pesquisa | bibliotecas lqes | publicações e teses | serviços técno-científicos | alunos e alumni 

LQES
lqes news
novidades de C&T&I e do LQES

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

LQES News anteriores

em foco

hot temas

 
NOVIDADES

A nanotechnology breath test for early-stage Parkinson's.

Symptoms of Parkinson's disease include tremor, loss of smell and neuropsychiatric problems. However, many people aren't diagnosed until their disease is well-advanced, which could limit their treatment options.

Now, researchers have tested a sensor to detect early-stage Parkinson's disease from the breath of patients. They report their results in ACS Chemical Neuroscience ("Sensor Array for Detection of Early Stage Parkinson’s Disease before Medication").



Scientists describe for the first time a clinical trial to distinguish between de novo PD and control subjects using an electronic system for detection of volatile molecules in exhaled breath (sensor array).


According to the Parkinson's Foundation, about 60,000 Americans are diagnosed with the movement disorder each year. But by the time most people experience symptoms, they have already lost many of the dopamine-producing neurons affected by the disease.

Diagnosing Parkinson's at an earlier stage, for example, at a routine doctor's visit, could help these patients begin neuroprotective therapy sooner.

To this end, John P.M. Finberg, Hossam Haick and their colleagues previously developed a device with an array of 40 sensors based on gold nanoparticles or single-walled carbon nanotubes.

Each sensor had a different chemical attached that could bind certain volatile molecules in the breath, and this binding changed the electrical resistance of the sensor.

The device detected differences in the exhaled breath of people already being treated for Parkinson's disease and healthy controls. Now, they wanted to see if the device could detect differences in the breath of patients with early-stage, not-yet-treated Parkinson's disease.

The researchers tested the device on the exhaled breath of 29 newly diagnosed patients who had not yet begun taking medication for their illness.

When comparing the sensor output to that of 19 control subjects of similar age, they found that the array detected early Parkinson's disease with 79 percent sensitivity, 84 percent specificity and 81 percent accuracy, which was better than a diagnostic smell test and almost as good as an ultrasound scan of the brain.

Although the device needs to be improved and validated by larger studies, the researchers say that it has potential as a small, portable system to screen at-risk individuals without the need for highly trained specialists.

American Chemical Society. Posted: July 25, 2018.


Assuntos Conexos:
Nanotecnologia: análise do hálito para detectar câncer e outras 16 doenças.



<< voltar para novidades

 © 2001-2019 LQES - lqes@iqm.unicamp.br sobre o lqes | políticas | link o lqes | divulgação | fale conosco